Loading...
XNASAMPH
Market cap1.75bUSD
Jan 10, Last price  
36.36USD
1D
-0.74%
1Q
-23.57%
Jan 2017
97.39%
IPO
263.24%
Name

Amphastar Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:AMPH chart
P/E
12.71
P/S
2.71
EPS
2.86
Div Yield, %
0.00%
Shrs. gr., 5y
2.70%
Rev. gr., 5y
16.94%
Revenues
644m
+29.14%
118,356,000204,323,000229,681,000210,461,000251,519,000255,165,000240,175,000294,666,000322,357,000349,846,000437,768,000498,987,000644,395,000
Net income
138m
+50.51%
7,752,00018,094,00011,862,000-10,699,000-2,787,00010,532,0004,508,000-5,738,00048,939,0001,097,00062,116,00091,386,000137,545,000
CFO
184m
+105.76%
19,096,000-1,650,00031,042,00021,052,00010,681,00038,560,00039,209,00038,191,00041,762,00057,266,00097,994,00089,181,000183,503,000
Dividend
Jun 11, 20100.3 USD/sh
Earnings
Feb 26, 2025

Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
IPO date
Jun 25, 2014
Employees
1,615
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
644,395
29.14%
498,987
13.98%
Cost of revenue
447,408
391,490
Unusual Expense (Income)
NOPBT
196,987
107,497
NOPBT Margin
30.57%
21.54%
Operating Taxes
31,833
23,477
Tax Rate
16.16%
21.84%
NOPAT
165,154
84,020
Net income
137,545
50.51%
91,386
47.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
(58,144)
(24,251)
BB yield
1.77%
1.65%
Debt
Debt current
8,248
6,049
Long-term debt
652,927
123,230
Deferred revenue
Other long-term liabilities
28,784
14,565
Net debt
389,157
(48,897)
Cash flow
Cash from operating activities
183,503
89,181
CAPEX
(38,166)
(24,034)
Cash from investing activities
(649,116)
(32,777)
Cash from financing activities
454,093
(26,439)
FCF
208,149
60,014
Balance
Cash
256,806
175,762
Long term investments
15,212
2,414
Excess cash
239,798
153,227
Stockholders' equity
400,796
263,105
Invested Capital
1,055,955
488,007
ROIC
21.39%
18.15%
ROCE
15.20%
16.57%
EV
Common stock shares outstanding
53,001
52,427
Price
61.85
120.74%
28.02
20.31%
Market cap
3,278,112
123.15%
1,469,005
26.70%
EV
3,667,269
1,420,108
EBITDA
238,764
136,238
EV/EBITDA
15.36
10.42
Interest
27,158
1,846
Interest/NOPBT
13.79%
1.72%